Economic burden associated with acute myeloid leukemia treatment. Issue 1 (2nd January 2016)

• Record Type: Journal Article
• Authors: Zeidan, Amer M; Mahmoud, Dalia; Kucmin-Bemelmans, Izabela T; Alleman, Cathelijne JM; Hensen, Marja; Skikne, Barry; Smith, B Douglas
• Is Part Of: Expert review of hematology. Volume 9:Issue 1(2016)
• Page Start: 79
• Page End: 89
• Publication Date: 2016-01-02
• Subjects: Acute myeloid leukemia -- chemotherapy -- cost of illness -- economic burden -- literature review -- stem cell transplantation -- treatment costs; Hematology -- Periodicals; 616.15005
• DOI: 10.1586/17474086.2016.1112735
• Languages: English
• ISSNs: 1747-4086

Abstract

Abstract : The economic burden associated with acute myeloid leukemia (AML) is poorly defined and understudied. The goal of this study is estimate the direct cost of illness for AML in the United States (US) and the United Kingdom (UK), by conducting a comprehensive literature review and calculating the average direct cost-of-illness per patient for the first 6 months of therapy. Patients were grouped by therapy: intensive chemotherapy alone; induction chemotherapy followed by allogeneic stem cell transplantation (alloSCT); low intensity therapy; and best supportive care. Data suggest that the pathways alloSCT, followed by intensive chemotherapy, are associated with the highest direct costs. Calculated direct costs suggest that they are higher in the US ($14, 014 for BSC-only to $352, 682 for alloSCT) than in the UK (£3708 [$5837] for BSC-only to £112, 545 [$177, 187]). AML appears to be associated with significant direct economic costs, but more studies are needed to fully assess the economic impact especially in relation to total and indirect costs.